Acorda Therapeutics completes acquisition of Civitas Therapeutics
Acorda announced it has completed its acquisition of Civitas Therapeutics for $525 million in cash and obtained global rights to CVT-301, a Phase 3 candidate for OFF episodes of Parkinson’s disease. The acquisition also included rights to the proprietary ARCUS® pulmonary delivery technology. October 22, 2014